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INTRODUCTION
Anthracyclines (AC) are highly effective chemotherapeutic
agents, whose full clinical potential is limited by cardiac toxicity
(ACT) [1–4]. ACT is progressive, may become manifested many
years after the completion of treatment and occurs at variable
threshold doses [5–8]. The evolution of AC-induced subclinical
cardiac dysfunction is not clearly understood and other than vigilant
monitoring, there are no explicit guidelines for its management
[6,9–11]. Therefore, each AC recipient requires monitoring for
cardiotoxicity for a long period of time, the duration of which is not
known.
Monitoring for ACT is most simply accomplished by echocar-
diographic measures, including fractional shortening (FS) and
ejection fraction (EF) [12]. However, these measures are dependent
on ventricular loading conditions and lack sensitivity for detecting
ACT [13,14]. FS alone is reduced in 28% of AC-treated patients,
whereas 57% have an abnormal left ventricular afterload, as
measured by end systolic wall stress (ESWS) or contractility
measured by the stress velocity index (SVI) [3]. These more
sophisticated parameters are technically difficult to obtain in
children. An objective, easily obtained biomarker of ventricular
function would greatly add to the clinical care of AC-treated
patients.
Plasma B-type natriuretic peptide (BNP) is a cardiac hormone
secreted from the ventricles, in response to ventricular volume and
pressure overload [15]. Levels increase in proportion to the severity
of congestive heart failure (CHF) in adults and children [16–18].
In the pediatric age group, values of BNP of 7 5.9 and
10.1 8.6 pgml1 have been reported in healthy boys and girls,
respectively [19]. Comparable BNP levels are noted in neonates
after closure of patent ductus arteriosus and children with
cardiomyopathy, without clinical signs of heart failure [20,21].
The role of BNP in screening for late onset ACT remains to be
elucidated. One previous study found plasma BNP to be signi-
ficantly elevated in patients with a reduction of FS or EF [22].
The rationale for our study was that plasma BNP may be elevated
in AC-treated patients with late cardiac dysfunction. Our primary
objective was to evaluate plasma BNP as a screening test for
detecting late onset AC-induced cardiac dysfunction, in com-
parison to detailed sensitive indices, not ordinarily available from a
clinical echo.
Since the mid 1990s, cumulative AC doses have been
empirically limited to below 550 mgm2 due to the high incidence
of clinically important cardiotoxicity observed above this dose [23].
More recently, a further dose reduction to below 250 mgm2 has
been suggested to reduce the incidence of ACT [9]. Limited
information is available about the impact of progressive AC dose
curtailment on the incidence of late cardiac dysfunction. Our
secondary aim, therefore, was to define the prevalence of cardiac
dysfunction using load-independent echocardiographic measures in
a cohort of patients treated with low cumulative AC doses.
MATERIALS AND METHODS
This prospective non-interventional study was conducted at
Children’s Hospital of Michigan, after approval by the Human
Investigation Committee. Patients were enrolled between October
2003 and June 2004 after obtaining written informed consent from
parents or guardians.
Selection Criteria
Patients who had completed AC chemotherapy at least 1 year
prior to enrollment were included. Patients with congenital heart
Background. Anthracyclines (AC) are useful antineoplastic
agents, whose utility is limited by progressive cardiotoxicity. Our
purpose was to evaluate plasma B-type natriuretic peptide (BNP), as
a screening test for detecting late cardiac dysfunction in AC-treated
children and to determine the prevalence of late cardiac dysfunction
at low cumulative AC doses. Materials and Methods. This was a
prospective study in which patients who had completed AC therapy
at least 1 year earlier, underwent a detailed echocardiogram and a
simultaneous BNP level. Cardiac dysfunction was defined as any one
of the following: shortening fraction (FS) <29%, rate corrected
velocity of circumferential fiber shortening (VCFc)<0.9 csec1, end
systolic wall stress (ESWS) >60 gcm2, abnormal VCFc: ESWS
ratio or decreased mitral inflow velocity (E/A) ratios, compared to
age-specific norms. Results. The cohort (n¼63) included 37 males
with a median age of 13.1 years (range, 6.5–26.5 years). Cardiac
dysfunction was found in 26 (41%) patients and in 40% of
patients who received cumulative doses <150 mgm2. ESWS was
the most common abnormality. Mean BNP levels in the subset with
abnormal function were significantly higher than the normal group
(23.4 25.3 vs. 14.2 8.9 pgml1, P¼0.02). Conclusions. Plasma
BNP was significantly elevated in AC-treated patients with late
cardiac dysfunction, although there was considerable overlap of
levels between groups with and without cardiac dysfunction. BNP
may need further evaluation as a serial index of cardiac function in
this population. Cardiac dysfunction was observed in a significant
proportion of patients, even at low cumulative AC doses. Pediatr
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disease, cardiomyopathy prior to initiation of chemotherapy, renal
failure (serum creatinine more than twice the age-specific norms),
patients who received mediastinal radiation, were pregnant or
critically ill, were excluded. Each patient underwent an echocardio-
gram and simultaneous blood draw for BNP assay for research
purposes.
Clinical Data
Clinical data obtained for each subject included demographics,
clinical diagnosis, the cumulative dose of AC received, time elapsed
since the completion of AC therapy, and cardiac symptoms.
Echocardiography
Echocardiograms were performed using a Phillips Sonos
5500 ultrasound machine. Each patient underwent M mode, 2D
and Doppler echocardiogram with simultaneous recording of
carotid pulse tracing, electrocardiogram, phonocardiogram, and
blood pressure. Echo parameters were selected to measure (a) left
ventricular systolic function (shortening fraction FS, ejection
fraction EF and rate corrected mean velocity of circumferential
fiber shortening VCFc), (b) afterload (end systolic wall stress
ESWS), (c) contractility (Stress velocity index SVI), and (d) left
ventricular diastolic function (peak E and A velocities and their
ratio). FS and EF were calculated as described [24,25]. Shortening
fraction below 29% and EF less than 64% were considered abnormal
[12,25]. VCFc was obtained by the method described by Colan et al.
[3,26] and considered abnormal below 0.90 csec1. ESWS was
calculated by the method described by Grossman et al. and
considered abnormal above 60 gcm2 [3,27]. The SVI or the
relationship between VCFc and ESWS were measured by the
method described by Colan et al. [26]. A VCFc value two standard
deviations below normal in relation to ESWS was considered to
represent abnormal contractility [26,28]. E/A ratio was obtained by
pulse Doppler at the mitral valve inflow and compared to established
normal values [29]. All echocardiograms were read by a single
cardiologist (MP) who was blinded to patient data and results of the
BNP assay.
Abnormal cardiac function was defined by any one of the
following criteria: FS <29%; VCFc <0.90 csec1; ESWS
>60 gcm2; abnormal VCFc: ESWS ratio; or decreased E/A ratio,
based on age-specific normal values. EF was not included in our
preset criteria of cardiac dysfunction due to inherent fallacies in its
echocardiographic measurement in the pediatric age group [25].
Plasma BNP Assay
Blood samples (3 ml) were collected in K-EDTA tubes within
3 hours of the echocardiogram and were centrifuged immediately at
3,500 rpm for 10 min. Platelet-free plasma was stored at 208C.
BNP assay was performed using the Triage BNP kit (Biosite
Diagnostic, San Diego, California).
Statistical Analysis
Statistical analyses were performed using SPSS (version 12)
software. Sample size was predetermined using a two-tailed test
with a significance (alpha) set at 0.05 to achieve a power of 81%,
based on the assumption that the BNP would be higher in patients
with abnormal heart function on echocardiogram by 20 pgdl1
(corresponding to means SD of 9 14.8 and 29 31.2, respec-
tively, based on a prior study) [22]. The number of patients required
to achieve a power of 80% was 23 in each group. Since 50–60%
of pediatric patients who receive AC have abnormal contractility
and/or afterload, we enrolled 63 patients with an expectation of two
nearly equal subsets—those with and without cardiac dysfunction
[3]. Data were expressed as mean SD for continuous variables and
as a number (percentage) for categorical variables. The two groups
were compared for continuous variables using the Student t-test for
independent samples [30]. Box and whisker plots of BNP levels
were used to show the distribution in the subgroups based on cardiac




Eighty patients were identified from the echo database in the
cardiology clinic. Two could not be traced and 15 patients refused
consent. Sixty-three patients were enrolled in the study including 37
(59%) males and 26 (41%) females. The median age at enrollment
was 13.1 years (range, 6.5–26.5) and the median interval since
completion of AC treatment was 3.8 years (range, 1.1–17.5). The
clinical diagnoses included acute lymphocytic leukemia in 29
(46%), Wilms tumor in 12 (19%), osteosarcoma in 12 (19%), and
lymphoma in 10 patients (16%). Five patients were on cardiac
medications (ACE inhibitors and digoxin) for ventricular dysfunc-
tion, of whom three were symptomatic with CHF, while two had
asymptomatic abnormal LV function. None of our patients had a
history of acute cardiac failure immediately following an AC dose.
The median cumulative dose of AC received was 165 mgm2
(range, 45–520; mean 160 mgm2). The cumulative AC dose
received was less than 150 mgm2 in 29 (46%) patients, between
150 and 300 mgm2 in 20 (31.7%), between 300 and 450 mg/m2 in
13 (20.6%) patients, and 520 mgm2 in 1 (1.5%). No patient
received more than 550 mgm2.
Echocardiographic Data
Twenty-six (41%) patients had at least one cardiac abnormality
on echocardiogram. The most frequently detected abnormality
was ESWS (range, 61–86 gcm2; median 66 gcm2; mean
68.7 gcm2) in 20 patients (31.7%). The nine (14%) patients who
had abnormal shortening fractions (range, 23–28; median 26%;
mean 26%) also had low EF (range 54–63, mean 60). Seven out of
63 (11.1%) had abnormal VCFc (range 0.76–0.9; median
0.84 csec1; mean 0.84 csec1) and 6 patients (9.5%) had an
abnormal stress velocity index. All three patients with clinical CHF
had low FS; two had four abnormal parameters (FS, ESWS, VCFc,
and SVI). Diastolic function (peak E/A velocities and their ratio)
was normal in all patients, with the E/A ratios ranging from 1.33 to
3.05, with a mean (SD) of 2.06 0.43 (median 2.03). Baseline
characteristics of the groups with normal and abnormal cardiac
function are shown (Table I). The two groups were similar in the
mean cumulative dose of AC received (204.7 100.6 mgm2
abnormal cardiac function vs. 223.1 127.7 mgm2 normal
cardiac function, P¼ 0.54) and interval post-AC treatment
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(5.6 4.4 years abnormal cardiac function and 5.1 3.7 years
normal cardiac function, P¼ 0.64).
Table II shows the number of patients with each cardiac
abnormality as a function of the cumulative dose received. Age at
treatment, interval of follow-up, and cumulative dose were not risk
factors for cardiac dysfunction on multivariate analysis. At all doses,
ESWS was the most frequently detected abnormality, present in 9 of
12 (75%) at cumulative AC doses below 150 mgm2, 7 of 10 (70%)
between 150 and 300 mgm2, and all 4 (100%) patients receiving
300–450 mgm2. Twelve out of 29 patients (40%) who had
received cumulative doses below 150 mgm2 had evidence of
cardiac dysfunction, including 4 patients who had received doses as
low as 90 mgm2. The patient who received a cumulative dose
of 520 mgm2 had normal cardiac function after 12.4 years of
follow-up.
Plasma BNP
The median BNP level for the cohort was 12.2 pgdl1 (range,
5–117 pgdl1). Mean (SD) plasma BNP levels were signi-
ficantly higher in the presence of abnormal cardiac function
(23.4 25.3 pgdl1, n¼ 26 vs. 14.2 8.9 pgdl1, n¼ 37,
P¼ 0.02; Fig. 1). Plasma BNP levels were higher when FS was
low (32.4 34.9 (n¼ 9) vs. 15.6 12.4 (n¼ 54), P< 0.008). When
all four systolic parameters were abnormal, plasma BNP was signi-
ficantly higher than when one to three parameters were abnormal
(69.2 67.1 (n¼ 2) vs. 19.6 17.3 (n¼ 24), P< 0.005). Plasma
BNP levels in the five subjects on cardiac medications were
significantly higher than the rest of the cohort (49.8 40.2 vs.
15.2 11.9 pgml1, P< 0.001). When the five patients on
medications were excluded, BNP levels remained significantly
higher when cardiac function was abnormal than when function was
normal (19.4 17.6 vs. 14.1 8.9, P¼ 0.02). Table III depicts the
mean plasma BNP levels in the subgroups with normal and
abnormal function for each echocardiographic parameter. Plasma
BNP was significantly higher in patients with abnormal FS, VCFc,
and SVI, but not ESWS.
DISCUSSION
Among AC-treated patients, 41% had an abnormality of cardiac
function at a mean follow-up interval of 5.2 years, the majority of
whom were asymptomatic. Nine (14%) patients had abnormal FS
and EF, the commonly used clinical parameters. The most sensitive
echo parameter for diagnosis of subclinical ACT was ESWS,
representing 80% of cardiac abnormalities, while contractility by
SVI was abnormal in only 24% of patients. Patients receiving doses
as low as 90 mgm2 had cardiac dysfunction. Plasma BNP was
significantly higher in patients with cardiac dysfunction and when
multiple echo parameters were abnormal. Plasma BNP was
significantly elevated in the presence of abnormal contractility,
although the elevation of BNP with increased ESWS did not reach
statistical significance. These findings assume importance, given the
growing numbers of AC treated patients and that AC use is mainly
limited by cardiotoxicity [5–7,31].
Our finding of the association of an elevated BNP with late AC-
induced cardiac dysfunction is similar to studies in adults, where a
significant increase in plasma BNP has been noted in AC-treated
patients with clinical or subclinical heart failure [32–34]. Previous
data in children are limited. While one previous study reported
elevation of plasma BNP (29 31.2 vs. 9 14.8 pgml1) in
patients with left ventricular dysfunction, compared to patients with
normal function, another reported higher BNP levels in the AC-
treated group as a whole, compared to untreated controls
(10.5 10.2 vs. 4.09 2.2 pgml1) [22,35]. Both studies enrolled
patients soon after completion of AC therapy when LV dysfunction
could represent acute toxicity, which is not predictive of late ACT.
Neither study excluded patients who had received chest radiation,
which can worsen ACT. Moreover, VCFc, ESWS, and SVI were
not utilized.
To our knowledge, ours is the largest study to evaluate plasma
BNP for the detection of late ACTusing sensitive echocardiographic
indices. We believe our finding of a mild but significant elevation in
plasma BNP with cardiac dysfunction is of clinical interest.
Although largely asymptomatic, an increase in plasma BNP may
Pediatr Blood Cancer DOI 10.1002/pbc





Male gender 26/37 (70%) 11/26 (42%) 0.12
Median age at time of diagnosis of cancer (years) 7.1 5.7 0.74
Median age at time of enrollment (years) 12.1 14.3 0.96
Median interval Post-AC-treatment (years) 3.8 3.6 0.64
Median cumulative anthracycline dose (mgm2) 165 180 0.54
TABLE II. Effect of Cumulative AC Dose on Echocardiographic Parameters of Cardiac Function
Dose/(n) Any abnormality Abnormal FS Abnormal EF Abnormal ESWS Abnormal VCFc Abnormal SVI
<150 mgm2 (29) 12 3 3 9 3 2
150–300 mgm2 (20) 10 5 5 7 3 3
300–450 mgm2 (13) 4 1 1 4 1 1
>450 mgm2 (1) 0 0 0 0 0 0
26 9 9 20 7 6
814 Aggarwal et al.
be a biochemical surrogate for subtle but potentially progressive
cardiac dysfunction. Indeed, the value of plasma BNP may lie in
serial monitoring, where a change in plasma BNP may predict a
decline in cardiac function for an individual patient. Further studies
are needed to evaluate plasma BNP in this manner. We are currently
conducting such a study.
A limitation of our study is that although plasma BNP was
significantly higher from a statistical standpoint in patients with
cardiac dysfunction, there was wide variation in the levels,
precluding determination of a cut-off level with high sensitivity
and specificity to discriminate between patients with normal cardiac
function from those without. The overlap of BNP levels makes it
unwise to use BNP as a sole screening method for ACT. BNP could
not differentiate abnormal from normal ESWS in our study (mean
BNP 23.5 abnormal vs. 15.4 normal ESWS). We suspect that our
small sample size was not powered to detect differences in BNP in
the subgroups for each individual echocardiographic parameter,
which larger studies may uncover.
We also report the prevalence and characteristics of late cardiac
dysfunction at curtailed AC doses, using sensitive echocardio-
graphic parameters. Our observed prevalence of late cardiac
abnormalities is similar to recent reports in which the mean
cumulative AC doses were approximately 300 mgm2 [9,36–39].
Our finding that even in the children who received cumulative
doses below 150 mgm2, 40% had late cardiac dysfunction is novel
and disturbing. We did not detect diastolic dysfunction in any of our
patients, conflicting with some previous studies but consistent with
others [40–42]. The established correlation between cumulative AC
dose and cardiac dysfunction was not noted in our dataset, probably
due to the small sample size.
Plasma BNP was significantly elevated in patients with late AC-
induced cardiac dysfunction, although there was considerable
overlap of levels in patients with normal and abnormal function.
Serial measures of plasma BNP merit further evaluation for
monitoring of AC-related cardiotoxicity. Even when treated with
low cumulative AC doses, about 40% of AC-treated children had
abnormal ventricular function.
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